Biological Information
Background Information:
CAL-101 (Idelalisib, GS-1101, Zydelig) is a synthetic drug that potently inhibits the phosphoinositide 3-kinase P110δ(PI3Kδ) (IC50=2.5nM), with 40-300-fold selectivity over p110α, β, and γ. CAL-101 is FDA approved for treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab. Provided as 10 mg of dry powder.
Usage
Product Type:
Control Ligands & Inhibitors
Application:
Drug Discovery & Development
Storage Conditions:
Store at -20°C. Please avoid multiple freeze/thaw cycles.
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Additional Information
Brand:
Eurofins DiscoverX®